MARKET

GALT

GALT

Galectin Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.660
-0.130
-7.26%
Closed 16:05 04/02 EDT
OPEN
1.760
PREV CLOSE
1.790
HIGH
1.990
LOW
1.650
VOLUME
266.38K
TURNOVER
--
52 WEEK HIGH
5.07
52 WEEK LOW
1.500
MARKET CAP
94.67M
P/E (TTM)
-3.8126
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GALT stock price target is 8.50 with a high estimate of 9.00 and a low estimate of 8.00.

EPS

GALT News

More
  • More COVID-19 actions - healthcare
  • seekingalpha · 17h ago
  • Galectin Therapeutics Update on the Impact of COVID-19
  • GlobeNewswire · 22h ago
  • Galectin Therapeutics Warns Plans To Initiate NASH-RX Trial In Q2 Could Be Impacted By Coronavirus Outbreak
  • Benzinga · 23h ago
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36

Industry

Biotechnology & Medical Research
+3.33%
Pharmaceuticals & Medical Research
+2.80%

Hot Stocks

Symbol
Price
%Change

About GALT

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.
More

Webull offers kinds of Galectin Therapeutics Inc stock information, including NASDAQ:GALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GALT stock news, and many more online research tools to help you make informed decisions.